Wedbush Expects Weaker Earnings for Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Research analysts at Wedbush decreased their Q2 2025 earnings per share (EPS) estimates for Kiniksa Pharmaceuticals in a research report issued on Tuesday, April 29th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $0.24 for the quarter, down from their previous forecast of $0.38. Wedbush currently has a “Outperform” rating and a $34.00 price target on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q3 2025 earnings at $0.25 EPS, Q4 2025 earnings at $0.28 EPS, FY2025 earnings at $0.89 EPS, FY2026 earnings at $1.48 EPS, FY2027 earnings at $1.98 EPS and FY2028 earnings at $2.31 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $137.79 million for the quarter, compared to analysts’ expectations of $128.35 million. During the same period in the previous year, the firm earned ($0.25) earnings per share. The business’s revenue was up 72.5% compared to the same quarter last year.

Several other analysts have also recently weighed in on the company. Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average target price of $38.00.

Kiniksa Pharmaceuticals Trading Down 0.3 %

NASDAQ:KNSA opened at $27.65 on Friday. Kiniksa Pharmaceuticals has a 12 month low of $17.38 and a 12 month high of $28.15. The company has a 50-day moving average price of $21.77 and a 200-day moving average price of $21.36. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of -197.49 and a beta of 0.31.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC raised its position in Kiniksa Pharmaceuticals by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after buying an additional 568 shares during the last quarter. Asset Management One Co. Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals during the first quarter valued at approximately $41,000. Wealthquest Corp purchased a new position in shares of Kiniksa Pharmaceuticals during the first quarter valued at approximately $42,000. Lazard Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals in the fourth quarter worth approximately $61,000. Finally, KLP Kapitalforvaltning AS bought a new stake in Kiniksa Pharmaceuticals in the 4th quarter worth approximately $158,000. 53.95% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, insider Ross Moat sold 18,259 shares of the firm’s stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $20.29, for a total transaction of $370,475.11. Following the completion of the sale, the insider now directly owns 9,415 shares in the company, valued at approximately $191,030.35. This trade represents a 65.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mark Ragosa sold 8,879 shares of the stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $23.10, for a total transaction of $205,104.90. Following the sale, the chief financial officer now owns 23,382 shares in the company, valued at approximately $540,124.20. The trade was a 27.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 218,548 shares of company stock worth $5,210,745 in the last 90 days. Insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.